These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30256948)

  • 1. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
    Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
    Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
    Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
    Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
    [No Abstract]   [Full Text] [Related]  

  • 3. Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.
    Yavarow ZA; Kang HR; Waskowicz LR; Bay BH; Young SP; Yen PM; Koeberl DD
    Hum Mol Genet; 2020 Jan; 29(2):286-294. PubMed ID: 31816064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency.
    Farah BL; Landau DJ; Sinha RA; Brooks ED; Wu Y; Fung SYS; Tanaka T; Hirayama M; Bay BH; Koeberl DD; Yen PM
    J Hepatol; 2016 Feb; 64(2):370-379. PubMed ID: 26462884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal endoplasmic reticulum stress is coupled to impaired autophagy in a mouse model of GSD Ia.
    Farah BL; Landau DJ; Wu Y; Sinha RA; Loh A; Bay BH; Koeberl DD; Yen PM
    Mol Genet Metab; 2017 Nov; 122(3):95-98. PubMed ID: 28888852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
    Lei Y; Hoogerland JA; Bloks VW; Bos T; Bleeker A; Wolters H; Wolters JC; Hijmans BS; van Dijk TH; Thomas R; van Weeghel M; Mithieux G; Houtkooper RH; de Bruin A; Rajas F; Kuipers F; Oosterveer MH
    Hepatology; 2020 Nov; 72(5):1638-1653. PubMed ID: 32083759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia.
    Cho JH; Kim GY; Pan CJ; Anduaga J; Choi EJ; Mansfield BC; Chou JY
    PLoS Genet; 2017 May; 13(5):e1006819. PubMed ID: 28558013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.
    Cho JH; Kim GY; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2018 Apr; 498(4):925-931. PubMed ID: 29545180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
    Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.
    Hoogerland JA; Peeks F; Hijmans BS; Wolters JC; Kooijman S; Bos T; Bleeker A; van Dijk TH; Wolters H; Gerding A; van Eunen K; Havinga R; Pronk ACM; Rensen PCN; Mithieux G; Rajas F; Kuipers F; Reijngoud DJ; Derks TGJ; Oosterveer MH
    J Inherit Metab Dis; 2021 Jul; 44(4):879-892. PubMed ID: 33739445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
    Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.
    Hijmans BS; Boss A; van Dijk TH; Soty M; Wolters H; Mutel E; Groen AK; Derks TGJ; Mithieux G; Heerschap A; Reijngoud DJ; Rajas F; Oosterveer MH
    Hepatology; 2017 Dec; 66(6):2042-2054. PubMed ID: 28727166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia.
    Kang HR; Waskowicz L; Seifts AM; Landau DJ; Young SP; Koeberl DD
    Mol Ther Methods Clin Dev; 2019 Jun; 13():265-273. PubMed ID: 30859111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context.
    Monteillet L; Gjorgjieva M; Silva M; Verzieux V; Imikirene L; Duchampt A; Guillou H; Mithieux G; Rajas F
    Mol Metab; 2018 Oct; 16():100-115. PubMed ID: 30100243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
    Cho JH; Lee YM; Bae SH; Chou JY
    Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
    Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
    Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia.
    Gjorgjieva M; Calderaro J; Monteillet L; Silva M; Raffin M; Brevet M; Romestaing C; Roussel D; Zucman-Rossi J; Mithieux G; Rajas F
    J Hepatol; 2018 Nov; 69(5):1074-1087. PubMed ID: 30193922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia.
    Brooks ED; Little D; Arumugam R; Sun B; Curtis S; Demaster A; Maranzano M; Jackson MW; Kishnani P; Freemark MS; Koeberl DD
    Mol Genet Metab; 2013 Jun; 109(2):161-70. PubMed ID: 23623482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.